ArticleNeurogastroenterology and motility2025
Prolonged Gastrointestinal Transit Times and Dysmotility in m.3243A>G Mitochondrial Disease.
Article in Neurogastroenterology and motility, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolomic signature reveals dysregulated lipoprotein profile in m.3243A>G carriers: a case-control study.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Dysregulation of the HSF1-Mediated UPRBiomolecules · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGastrointestinal (GI) symptoms are frequently reported from carriers of the pathogenic mitochondrial DNA variant m.3243A>G, causing decreased mitochondrial adenosine triphosphate (ATP) production. ATP deficiency may adversely affect both autonomic neurogenic and myogenic regulation of GI motility, contributing to the symptoms. This study examined if carriers of m.3243A>G exhibit GI dysmotility, characterized as prolonged segmental transit times and decreased motility indices.
methodsTwenty-two Danish carriers of m.3243A>G and 22 healthy, sex- and age-matched controls with body mass index < 26 kg/m KEY
resultsMedian [interquartile range] GI symptoms were higher in carriers of m.3243A>G assessed with GCSI (1.3 [0.4-1.9] vs. 0.2 [0.0-0.4], p < 0.001) and GSRS (2.1 [1.4-3.3] vs. 1.1 [1.0-1.2], p < 0.001). m.3243A>G carriers further exhibited prolonged median [interquartile range] gastric emptying time (221 min [150-348] vs. 165 min [137-199], p = 0.02), colonic transit time (2283 min [1082-5153] vs. 1014 min [840-2451], p = 0.03) and decreased mean [confidence interval] colonic motility index (114.7 mmHg*s/min [86.2; 143.3] vs. 168.6 mmHg*s/min [129.9; 207.3], p = 0.03) compared to controls. However, these measures were not associated with the perceived GI symptoms. CONCLUSION & INFERENCES: Carriers of m.3243A>G demonstrated gastroenteropathy, evident as prolonged gastric and colonic transit time and decreased colonic motility index. It is plausible that the negative effect of impaired mitochondrial ATP production impacts the regulation of GI motility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.